QUIANA COOPER: Open Payments
NPI 1265052047 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,245 in 54 payments from 19 companies in 2025. Trend: 2023 $1,813 · 2024 $1,114 · 2025 $1,245
Food & beverage: $1,245
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $163 |
| Neurocrine BioSciences, Inc. | 4 | $134 |
| Almatica Pharma LLC | 4 | $106 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| ABBVIE INC. | 5 | $103 |
| Collegium Pharmaceutical, Inc. | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Alkermes, Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
Products named: CAPLYTA, INGREZZA, LOREEV XR, VRAYLAR, Jornay PM, REXULTI, ARISTADA, HETLIOZ.
Industry payments across CA — which companies pay providers there.
